Literature DB >> 19925748

First-year Medicare Part D prescription drug benefits: medication access and continuity among dual eligible psychiatric patients.

Joyce C West1, Joshua E Wilk, Donald S Rae, Irvin L Muszynski, Maritza Rubio-Stipec, Carol L Alter, Karen E Sanders, Stephen Crystal, Darrel A Regier.   

Abstract

OBJECTIVE: This study provides national data on medication access and continuity problems experienced during the first year of the Medicare Part D prescription drug program, which was implemented on January 1, 2006, among a national sample of Medicare and Medicaid "dual eligible" psychiatric patients.
METHOD: Practice-based research methods were used to collect clinician-reported data across the full range of public and private psychiatric treatment settings. A random sample of psychiatrists was selected from the American Medical Association Physician Masterfile. Among these physicians, 1,490 provided clinically detailed data on a systematically selected sample of 2,941 dual eligible psychiatric patients.
RESULTS: Overall, 43.3% of patients were reported to be unable to obtain clinically indicated medication refills or new prescriptions in 2006 because they were not covered or approved; 28.9% discontinued or temporarily stopped their medication(s) as a result of prescription drug coverage or management issues; and 27.7% were reported to be previously stable on their medications but were required to switch medications. Adjusting for case mix to control for sociodemographic and clinical confounders, the predicted probability of an adverse event among patients with medication access problems was 0.64 compared to 0.36 for those without access problems (P < .0001). All prescription drug utilization management features studied were associated with increased medication access problems (P < .0001). Adjusting for patient case mix, patients with "step therapy" (P < .0001), limits on medication number/dosing (P < .0001), or prior authorization (P < .0001) had 2.4 to 3.4 times the increased likelihood of an adverse event.
CONCLUSIONS: More effective Part D policies and management practices are needed to promote clinically safer and appropriate pharmacotherapy for psychiatric patients to enhance treatment outcomes. Copyright 2010 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19925748     DOI: 10.4088/JCP.08m04608whi

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  6 in total

Review 1.  Medicare part D and long-term care: a systematic review of quantitative and qualitative evidence.

Authors:  Camilla B Pimentel; Kate L Lapane; Becky A Briesacher
Journal:  Drugs Aging       Date:  2013-09       Impact factor: 3.923

Review 2.  Medicare Part D's effect on the under- and overuse of medications: a systematic review.

Authors:  Jennifer M Polinski; Julie M Donohue; Elaine Kilabuk; William H Shrank
Journal:  J Am Geriatr Soc       Date:  2011-08-01       Impact factor: 5.562

3.  Roles of community helpers in using the Medicare Part D benefit.

Authors:  Melissa Anne Hensley
Journal:  J Health Care Poor Underserved       Date:  2011-02

4.  Dual eligibles with mental disorders and Medicare part D: how are they faring?

Authors:  Julie M Donohue; Haiden A Huskamp; Samuel H Zuvekas
Journal:  Health Aff (Millwood)       Date:  2009 May-Jun       Impact factor: 6.301

5.  Part D and dually eligible patients with mental illness: medication access problems and use of intensive services.

Authors:  Haiden A Huskamp; Joyce C West; Donald S Rae; Maritza Rubio-Stipec; Darrel A Regier; Richard G Frank
Journal:  Psychiatr Serv       Date:  2009-09       Impact factor: 3.084

6.  Impact of Medicare Part D on mental health treatment and outcomes for dual eligible beneficiaries with HIV.

Authors:  Nadya Belenky; Brian W Pence; Stephen R Cole; Stacie B Dusetzina; Andrew Edmonds; Jonathan Oberlander; Michael Plankey; Adebola Adedimeji; Tracey E Wilson; Jennifer Cohen; Mardge H Cohen; Joel E Milam; Adaora A Adimora
Journal:  AIDS Care       Date:  2018-09-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.